Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 4

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Gynecologic 2

Conditions

Ovarian Neoplasms 2Lung Neoplasms 2

Interventions

Paclitaxel 337pembrolizumab 333Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 240Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 170Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 119Prednisone 118Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Doxorubicin 98Leucovorin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 78Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Has results × Pafolacianine × Clear all
NCT02872701 2023-03-24

OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

On Target Laboratories, LLC

Phase 2 Completed
100 enrolled 15 charts
Thoracic

Lung Neoplasms

NCT04241315 2023-03-23

Elucidate

On Target Laboratories, LLC

Phase 3 Completed
112 enrolled 15 charts
Thoracic

Lung Neoplasms

NCT02317705 2022-06-21

Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer

On Target Laboratories, LLC

Phase 2 Completed
48 enrolled 10 charts
Gynecologic

Ovarian Neoplasms

NCT03180307 2022-02-04

OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

On Target Laboratories, LLC

Phase 3 Completed
140 enrolled 11 charts 1 FDA
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡